1 Most thyroid nodules are detected incidentally when imaging is performed for another indication. In the TR3 category, there was a gradual difference in cancer rate in those 1-2 cm (6.5%), and those 2-3 cm (8.4%) and those>3 cm (11.3%). Thyroid Tirads 4: Thyroid lesions with suspicious signs of malignancy. Second, the proportion of patients in the different ACR TIRADS (TR) categories may, or may not, reflect the real-world population (Table 1). The present study evaluated the risk of malignancy in solid nodules>1 cm using ACR TI-RADS. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). We aimed to assess the performance and costs of the American College of Radiology Thyroid Image Reporting And Data System (ACR-TIRADS). FOIA Search for other works by this author on: University of Otago, Christchurch School of Medicine, Department of Endocrinology, St Vincents University Hospital, Department of Radiology, St Vincents University Hospital, Dublin 4 and University College Dublin, Biostatistician, Department of Medical & Womens Business Management, Canterbury District Health Board, Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging, The prevalence of thyroid nodules and an analysis of related lifestyle factors in Beijing communities, Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis, Occult papillary carcinoma of the thyroid. Anti-thyroid medications. Therefore, taking results from this data set and assuming they would apply to the real-world population raises concerns. We then compare the diagnosis performance of C-TIRADS, CEUS, and CEUS-TIRADS by sensitivity, specificity, and accuracy. Such a study should also measure any unintended harm, such as financial costs and unnecessary operations, and compare this to any current or gold standard practice against which it is proposed to add value. Other similar systems are in use internationally (eg, Korean-TIRADS [14] and EU-TIRADS [15]). Keywords: Differentiation of Thyroid Nodules (C-TIRADS 4) by Combining Contrast These final validation sets must fairly represent the population upon which the test is intended to be applied because the prevalence of the condition in the test population will critically influence the test performance, particularly the positive predictive value (PPV) and negative predictive value (NPV). Unauthorized use of these marks is strictly prohibited. Approach to Bethesda system category III thyroid nodules - PubMed 2020 Mar 10;4 (4):bvaa031. The. proposed a system with five categories, which, like BI-RADS, each carried a management recommendation 2. To illustrate the effect of the size cutoffs we have given 2 examples, 1 where the size cutoffs are not discriminatory and the cancer rate is the same above and below the size cutoff, and the second example where the cancer risk of the nodule doubles once the size goes above the cutoff. Thyroid nodules could be classified into one of 10 ultrasound patterns, which had a corresponding TI-RADS category. Unfortunately, the collective enthusiasm for welcoming something that appears to provide certainty has perhaps led to important flaws in the development of the models being overlooked. Your email address will not be published. The system is sometimes referred to as TI-RADS French 6. Thyroid Imaging Reporting and Data System (TI-RADS): A User's Guide Cao H, Fan Q, Zhuo S, Qi T, Sun H, Rong X, Xiao X, Zhang W, Zhu L, Wang L. J Ultrasound Med. In 2009, Park et al. The system has fair interobserver agreement 4. However, many patients undergoing a PET scan will have another malignancy. So just using ACR TIRADS as a rule-out test could be expected to leave 99% of undiagnosed cancers amongst the remaining 75% of the population, in whom the investigation and management remains unresolved. Furthermore, we are presuming other clinical factors (ie, palpability, size, number, symptoms, age, gender, prior radiation exposure, family history) add no diagnostic value above random selection. The low pretest probability of important thyroid cancer and the clouding effect of small clinically inconsequential thyroid cancers makes the development of an effective real-world test incredibly difficult. At the time the article was created Praveen Jha had no recorded disclosures. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Such validation data sets need to be unbiased. Results: In which, divided into groups such as: Malignant 3.3%; malignancy 9.2%; malignant 44.4 - 72.4%, malignant. Such guidelines do not detail the absolute risk of finding or missing a cancer, nor the often excellent outcome of the treatment of thyroid cancer, nor the potential for unnecessary operations. 'Returning to TI-RADS' may assist with triage of indeterminate thyroid The pathological result was papillary thyroid carcinoma. This allows patients with a TR1 or TR2 nodule to be reassured that they have a low risk of thyroid cancer, rather than a mixture of nodules (not just TR1 or TR2) not being able to be reassured. With the right blood tests, you can see if you have a thyroid nodule, and if so, you can treat it with radioactive iodine. Thyroid nodules - Diagnosis and treatment - Mayo Clinic This causes the nodules to shrink and signs and symptoms of hyperthyroidism to subside, usually within two to three months. Objective: To determine whether the size of thyroid nodules in ACR-TIRADS ultrasound categories 3 and 4 is correlated with the Bethesda cytopathology classification. Horvath E, Majlis S, Rossi R et-al. Radiofrequency ablation uses a probe to access the benign nodule under ultrasound guidance, and then treats it with electrical current and heat that shrinks the nodule. published a simplified TI-RADS that was prospectively validated 5. TIRADS Management Guidelines in the Investigation of Thyroid Nodules tirads 4 thyroid nodule treatment - Investigative Signal For example, a previous meta-analysis of more than 25,000 FNAs showed 33% were in these groups [17]. tirads 4 thyroid nodule treatment - yaeyamasyoten.com The process of establishing of CEUS-TIRADS model. Risk Stratification of Thyroid Nodules Using the Thyroid Imaging The Thyroid Imaging Reporting and Data System (TI-RADS) of the American College of Radiology (ACR) was designed in 2017 with the intent to decrease biopsies of benign nodules and improve overall . The risk of malignancy was derived from thyroid ultrasound (TUS) features. The more carefully one looks for incidental asymptomatic thyroid cancers at autopsy, the more are found [4], but these do not cause unwellness during life and so there is likely to be no health benefit in diagnosing them antemortem. If one decides to FNA every TR5 nodule, from the original ACR TIRADS data set, 34% were found to be cancerous, but note that this data set likely has double the prevalence of thyroid cancer compared with the real-world population. Now, the first step in T3N treatment is usually a blood test. Noticeably benign pattern (0% risk of malignancy) TI-RADS 3: Probably benign nodules (<5% risk of malignancy) TI-RADS 4: 4a - Undetermined nodules (5-10% risk of malignancy) Score of 1. 2022 Jul;41(7):1753-1761. doi: 10.1002/jum.15858. In view of their critical role in thyroid nodule management, more improved TI-RADSs have emerged. The consequences of these proportions are highly impactful when considering the real-world performance of ACR-TIRADS. Findings of a large, prospective multicenter study from Egypt, published in the August 2019 issue of the European Journal . This site needs JavaScript to work properly. TI-RADS score - Ultrasound Assessment of Thyroid Nodules - GP Voice Alternatively, if random FNAs are performed in 1 in 10 nodules, then 4.5 thyroid cancers (4-5 people per 100) will be missed. The frequency of different Bethesda categories in each size range . Test performance in the TR3 and TR4 categories had an accuracy of less than 60%. For a rule-out test, sensitivity is the more important test metric. Tests and procedures used to diagnose thyroid cancer include: Physical exam. Using TR5 as a rule-in test was similar to random selection (specificity 89% vs 90%). Hypoechoic Nodule on Thyroid: Cancer Risk, Next Steps, Outlook - Healthline Risk of Malignancy in Thyroid Nodules Using the American - PubMed doi: 10.3390/diagnostics11081374 Thyroid Nodules: When to Worry | Johns Hopkins Medicine The cost-effective diagnosis or exclusion of consequential thyroid cancer is an everyday problem faced by all thyroid clinicians. The authors proposed the following criteria, based on French Endocrine Society guidelines, for when to proceed with fine needle aspiration biopsy: ADVERTISEMENT: Supporters see fewer/no ads, Please Note: You can also scroll through stacks with your mouse wheel or the keyboard arrow keys. We have detailed the data set used for the development of ACR TIRADS [16] in Table 1, plus noted the likely cancer rates in the real world if one assumes that the data set cancer prevalence (10.3%) is double that in the population upon which the test is intended to be used (pretest probability of 5%). The problem is that many people dont know that they have a thyroid nodule, so they dont know how to treat it. Frontiers | Differentiation of Thyroid Nodules (C-TIRADS 4) by For those that also have 1 or more TR3, TR4, or TR5 nodules on their scan, they cannot have thyroid cancer ruled out by TIRADS because the possibility that their non-TR1/TR2 nodules may be cancerous is still unresolved. Thyroid nodules with TIRADS 4 and 5 and diameter lower than 12 mm, are highly suspicious for malignancy and should be considered as indications for fine needle aspiration biopsy. Ultrasonogram Reporting System for Thyroid Nodules Stratifying Cancer 19 (11): 1257-64. Third, when moving on from the main study in which ACR TIRADS was developed [16] to the ACR TIRADS white paper recommendations [22], the TIRADS model changed by the addition of a fifth US characteristic (taller than wide), plus the addition of size cutoffs. A recent meta-analysis comparing different risk stratification systems included 13,000 nodules, mainly from retrospective studies, had a prevalence of cancer of 29%, and even in that setting the test performance of TIRADS was disappointing (eg, sensitivity 74%, specificity 64%, PPV 43%, NPV 84%), and similar to our estimated values of TIRADS test performance [38]. 2. Ultrasound classification of thyroid nodules: does size matter? . TIRADS ( T hyroid I maging R eporting and D ata S ystem) is a 5-point scoring system for thyroid nodules on ultrasound, developed by the American College of Radiology ( hence also termed as ACR- TIRADS). Diagnosis and Management of Small Thyroid Nodules: A Comparative Study with Six Guidelines for Thyroid Nodules. Among the 228 C-TIRADS 4 nodules, 69 were determined as C-TIRADS 4a, 114 were C-TIRADS 4b, and 45 were C-TIRADS 4c. The chance of finding cancer is 1 in 20, whereas the chance of testing resulting in an unnecessary operation is around 1 in 7. Full data including 95% confidence intervals are given elsewhere [25]. Radzina M, Ratniece M, Putrins DS, Saule L, Cantisani V. Cancers (Basel). However, there are ethical issues with this, as well as the problem of overdiagnosis of small clinically inconsequential thyroid cancer. Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L. Middleton WD, Teefey SA, Reading CC, et al. The probability of malignancy was based on an equation derived from 12 features 2. We first estimate the performance of ACR TIRADS guidelines recommended approach to the initial decision to perform FNA, by using TR1 or TR2 as a rule-out test, or using TR5 as a rule-in test because applying TIRADS at the extremes of pretest cancer risk (TR1 and TR2 for lowest risk, and TR5 for highest risk), is most likely to perform best. If your doctor found a hypoechoic nodule during an ultrasound, they may simply do some additional testing to make sure there's . The detection rate of thyroid cancer has increased steeply with widespread utilization of ultrasound (US) and frequent incidental detection of thyroid nodules with other imaging modalities such as computed tomography, magnetic resonance imaging, and, more recently, positron emission tomography-computed tomography, yet the mortality from thyroid cancer has remained static [10, 11]. The prevalence of incidental thyroid cancer at autopsy is around 10% [3]. We then compare the diagnosis performance of C-TIRADS, CEUS, and CEUS-TIRADS by sensitivity, specificity, and accuracy. A study that looked at all nodules in consecutive patients (eg, perhaps FNA of every nodule>10 mm) would be required to get an accurate measure of the cancer prevalence in those nodules that might not typically get FNA. Thyroid nodules are a common finding, especially in iodine-deficient regions. TI-RADS: Diagnostically valid, high reproducibility in ID'ing malignant If you assume that FNA is done as per reasonable application of TIRADS recommendations (in all patients with TR5 nodules, one-half of patients with TR4 nodules and one-third of patients with TR3 nodules) and the proportion of patients in the real world have roughly similar proportion of TR nodules as the data set used, then 100 US scans would result in FNAs of about one-half of all patients scanned (of data set, 16% were TR5, 37% were TR4, and 23% were TR3, so FNA number from 100 scans=16+(0.537)+(0.323)=42). The sensitivity, specificity, and accuracy of CEUS were 78.7%, 87.5%, and 83.3% respectively. 4b - Suspicious nodules (10-50% risk of malignancy) Score of 2. This is likely an underestimate of the number of scans needed, given that not all nodules that are TR1 or TR2 will have purely TR1 or TR2 nodules on their scan. To show the best possible performance of ACR TIRADS, we are comparing it to clinical practice in the absence of TIRADS or other US thyroid nodule stratification tools, and based on a pretest probability of thyroid cancer in a nodule being 5%, where 1 in 10 nodules are randomly selected for FNA. In addition, changes in nomenclature such as the recent classification change to noninvasive follicular thyroid neoplasm with papillary-like nuclear features would result in a lower rate of thyroid cancer if previous studies were reported using todays pathological criteria. Second, we then apply TIRADS across all 5 nodule categories to give an idea how TIRADS is likely to perform overall. MeSH EU-TIRADS 2 category comprises benign nodules with a risk of malignancy close to 0%, presented on sonography as pure/anechoic cysts ( Figure 1A) or entirely spongiform nodules ( Figure 1B ). The performance of any diagnostic test in this group has to be truly exceptional to outperform random selection and accurately rule in or rule out thyroid cancer in the TR3 or TR4 groups. Later arrival time, hypo-enhancement, heterogeneous enhancement, centripetal enhancement, and rapid washout were risk factors of malignancy in multivariate analysis. A 35-year-old woman with a nodule in the left-lobe of her thyroid gland. The difference was statistically significant (P<0.05). Zhonghua Yi Xue Za Zhi. We found sensitivity and PPV with TIRADS was poor, but was better than random selection (sensitivity 53% vs 1%, and PPV 34% vs 1%) whereas specificity, NPV, and accuracy was no better with TIRADS compared with random selection (specificity 89% vs 90%, NPV 94% vs 95%, and accuracy 85% vs 85%), Table 2 [25]. The first time Tirads 3 after cytology is benign, but you do not say how many mm and after 3 months of re-examination, it was . The figures that TIRADS provide, such as cancer prevalence in certain groups of patients, or consequent management guidelines, only apply to populations that are similar to their data set. In patients with thyroid nodules, ultrasonography (US) has been established as a primary diagnostic imaging method and is essential for treatment decision. The more FNAs done in the TR3 and TR4 groups, the more indeterminate FNAs and the more financial costs and unnecessary operations. There are two suspicious signs with the nodule (solid and irregular margin) and it was defined as C-TIRADS 4b. A subdivision into 4a (malignancy between 5 and 10%) and 4b (malignancy between 10 and 80%) was optional. An official website of the United States government. However, the consequent management guidelines are difficult to justify at least on a cost basis for a rule-out test, though ACR TIRADS may provide more value as a rule-in test for a group of patients with higher cancer risk. Based on the methodology used to acquire the data set, the gender bias, and cancer rate in the data set, it is unlikely to be a fair reflection of the population upon which the test is intended to be applied, and so cannot be considered a true validation set. A negative result with a highly sensitive test is valuable for ruling out the disease. At best, only a minority of the 3% of cancers would show on follow-up imaging features suspicious for thyroid cancer that correctly predict malignancy. There are a number of additional issues that should be taken into account when examining the ACR TIRADS data set and resultant management recommendations. Authors doi: 10.12659/MSM.936368. However, the ACR TIRADS flow chart with its sharp cutoffs conveys a degree of certainty that may not be valid and may be hard for the clinician to resist. Thyroid Cancer: Diagnosis, Treatment and Follow-Up | IntechOpen ectomy, Parotid gland surgery, Transoral laser microsurgery, Transoral robotic surgery, Oral surgery, Parotid gland tumor, Skin cancer, Tonsil cancer, Throat cancer, Salivary gland tumor, Salivary gland cancer, Thyroid nodule, Head and neck cancer, Laryngeal cancer, Tongue . The NNS for ACR TIRADS is such that it is hard to justify its use for ruling out thyroid cancer (NNS>100), at least on a cost/benefit basis. Those working in this field would gratefully welcome a diagnostic modality that can improve the current uncertainty. A total of 228 thyroid nodules (C-TIRADS 4) were estimated by CEUS. 2013;168 (5): 649-55. The more important test metric for diagnosing a disease is the specificity, where a positive test helps rule-in the disease. Epub 2021 Oct 28. eCollection 2022. By CEUS-TIRADS diagnostic model combining CEUS with C-TIRADS, a total of 127 cases were determined as malignancy (111 were malignant and 16 were benign) and 101 were diagnosed as benign ones (5 were malignant and 96 were benign). TIRADS 5: probably malignant nodules (malignancy >80%). However, in the data set, only 25% of all nodules were categorized as TR1 or TR2 and these nodules harbored only 1% of all thyroid cancers (9 of 343). This data set was a subset of data obtained for a previous study and there are no clear details of the inclusion and exclusion criteria, including criteria for FNA. It is important to validate this classification in different centres. In a clinical setting, this would typically be an unselected sample of the test population, for example a consecutive series of all patients with a thyroid nodule presenting to a clinic, ideally across multiple centers. The findings that ACR TIRADS has methodological concerns, is not yet truly validated, often performs no better than random selection, and drives significant costs and potential harm, are very unsettling but result from a rational and scientific assessment of the foundational basis of the ACR TIRADS system. What does a hypoechoic thyroid nodule mean? - Medical News Today The high prevalence of thyroid nodules combined with the generally indolent growth of thyroid cancer present a challenge for optimal patient care. That particular test is covered by insurance and is relatively cheap. Such data should be included in guidelines, particularly if clinicians wish to provide evidence-based guidance and to obtain truly informed consent for any action that may have negative consequences. Learn how t. Cystic or almost completely cystic 0 points. The results were compared with histology findings. 8600 Rockville Pike Advances in knowledge: The study suggests TIRADS and thyroid nodule size as sensitive predictors of malignancy. Once the test is considered to be performing adequately, then it would be tested on a validation data set. A key factor is the low pretest probability of important thyroid cancer but a higher chance of finding thyroid cancers that are very unlikely to cause ill health during a persons lifetime. Radiology. 3. PLoS ONE. FNA, fine-needle aspiration; US, ultrasound; CEUS, contrast-enhanced ultrasound; C-TIRADS, Chinese imaging reporting and data system. 4. spiker54. The management guidelines may be difficult to justify from a cost/benefit perspective. Performance of Contrast-Enhanced Ultrasound in Thyroid Nodules: Review of Current State and Future Perspectives. doi: 10.1007/s12020-020-02441-y Thyroid Nodules. [Clinical Application of the 2021 Korean Thyroid Imaging Reporting and 2022 Jun 7;28:e936368. Thus, the absolute risk of missing important cancer goes from 5% (with no FNAs) to 2.5% using TIRADS and FNA of all TR5, so NNS=100/2.5=40. TIRADS does not perform to this high standard. However, these assumptions have intentionally been made to favor the expected performance of ACR-TIRADS, and so in real life ACR-TIRADS can be expected to perform less well than we have illustrated. No focal lesion. It helps to decide if a thyroid nodule is benign or malignant by combining multiple features on ultrasound. The ACR TIRADS management flowchart also does not take into account these clinical factors. Bessey LJ, Lai NB, Coorough NE, Chen H, Sippel RS. Park JY, Lee HJ, Jang HW, Kim HK, Yi JH, Lee W, Kim SH. The gold test standard would need to be applied for comparison. The true test performance can only be established once the optimized test has been applied to 1 or more validation data sets and compared with the existing gold standard test. Castellana M, Castellana C, Treglia G, Giorgino F, Giovanella L, Russ G, Trimboli P. Oxford University Press is a department of the University of Oxford. The sensitivity, specificity, and accuracy of C-TIRADS were 93.1%, 55.3%, and 74.6% respectively. The process of validation of CEUS-TIRADS model. TIRADS Management Guidelines in the Investigation of Thyroid Nodules In: Thyroid 26.1 (2016), pp. PPV was poor (20%), NPV was no better than random selection, and accuracy was worse than random selection (65% vs 85%). The costs depend on the threshold for doing FNA. Very probably benign nodules are those that are both. Ultrasonographic scoring systems such as the Thyroid Imaging Reporting and Data System (TIRADS) are helpful in differentiating between benign and malignant thyroid nodules by offering a risk stratification model. The test that really lets you see a nodule up close is a CT scan. TIRADS Management Guidelines in the Investigation of Thyroid Nodules; Illustrating the Concerns, Costs, and Performance TIRADS Management Guidelines in the Investigation of Thyroid Nodules; Illustrating the Concerns, Costs, and Performance J Endocr Soc. A robust validation study is required before the performance and cost-benefit outcomes of any of the TIRADS systems can be known. That particular test is covered by insurance and is relatively cheap. It has been retrospectively applied to thyroidectomy specimens, which is clearly not representative of the patient presenting with a thyroid nodule [34-36], and has even been used on the same data set used for TIRADS development, clearly introducing obvious bias [32, 37]. ACR TIRADS performed poorly when applied across all 5 TR categories, with specificity lower than with random selection (63% vs 90%). They are found . Chinese thyroid imaging reporting and data system(C-TIRADS); contrast-enhanced ultrasound (CEUS); differentiation; thyroid nodules; ultrasound (US). In CEUS analysis, it reflected as later arrival time, hypo-enhancement, heterogeneous and centripetal enhancement, getting a score of 4 in the CEUS model. These figures cannot be known for any population until a real-world validation study has been performed on that population. Management of nodules with initially nondiagnostic results of thyroid fine-needle aspiration: can we avoid repeat biopsy? PET-positive thyroid nodules have a relatively high malignancy rate of 35%. Thyroid nodules - Doctors and departments - Mayo Clinic Because the data set prevalence of thyroid cancer was 10%, compared with the generally accepted lower real-world prevalence of 5%, one can reasonably assume that the actual cancer rate in the ACR TIRADS categories in the real world would likely be one-half that quoted from the ACR TIRADS data set, which we illustrate in the following section. Refer to separate articles for the latest systems supported by various professional societies: A TI-RADS was first proposed by Horvath et al. Before If a clinician does no tests and no FNAs, then he or she will miss all thyroid cancers (5 people per 100). So, for 100 scans, if FNA is done on all TR5 nodules, this will find one-half of the cancers and so will miss one-half of the cancers. The US follow-up is mainly recommended for the smaller TR3 and TR4 nodules, and the prevalence of thyroid cancer in these groups in a real-world population with overall cancer risk of 5% is low, likely<3%. TR5 in the data set made up 16% of nodules, in which one-half of the thyroid cancers (183/343) were found. Those wishing to continue down the investigative route could then have US, using TIRADS or ATA guidelines or other measures to offer some relative risk-stratification. Cawood T, Mackay GR, Hunt PJ, OShea D, Skehan S, Ma Y. Russ G, Bigorgne C, Royer B, Rouxel A, Bienvenu-Perrard M. Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY. in 2009 1. A prospective validation study that determines the true performance of TIRADS in the real-world is needed. High Risk Thyroid Nodule Discrimination and Management by Modified TI Your health care provider will examine your neck to feel for changes in your thyroid, such as a lump (nodule) in the thyroid. Using TR1 and TR2 as a rule-out test had excellent sensitivity (97%), but for every additional person that ACR-TIRADS correctly reassures, this requires >100 ultrasound scans, resulting in 6 unnecessary operations and significant financial cost. Objectives: -, Takano T. Overdiagnosis of Juvenile Thyroid Cancer: Time to Consider Self-Limiting Cancer. Doctors use radioactive iodine to treat hyperthyroidism. These cutoffs are somewhat arbitrary, with conflicting data as to what degree, if any, size is a discriminatory factor. When it reflected an absent enhancement in CEUS, the nodule was judged as CEUS-TIRADS 3. Prediction of thyroid nodule malignancy using thyroid imaging - PubMed Save my name, email, and website in this browser for the next time I comment. Thyroid nodules come to clinical attention when noted by the patient; by a clinician during routine physical examination; or during a radiologic procedure, such as carotid ultrasonography, neck or chest computed tomography (CT), or positron emission tomography (PET) scanning. eCollection 2020 Apr 1. Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography. 3, 4 The modified TI-RADS based on the ACR TI-RADS scoring system was sponsored by Wang et al. We realize that such factors may increase an individuals pretest probability of cancer and clinical decision-making would change accordingly (eg, proceeding directly to FNA), but we here ascribe no additional diagnostic value to avoid overestimating the performance of the clinical comparator.
Arnold Palmer Diet Half And Half Caffeine,
Cocktails Made With Peanut Butter Whiskey,
Street Map Of Stillwater, Oklahoma,
Articles T